Research programme: cancer therapeutics - Azaya TherapeuticsAlternative Names: ATI-0721; ATI-1150; ATI-1186; ATI-1230
Latest Information Update: 05 Sep 2008
At a glance
- Originator Azaya Therapeutics
- Mechanism of Action DNA topoisomerase I inhibitors; Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Sep 2008 Preclinical development is ongoing in USA
- 18 May 2007 Preclinical trials in Cancer in USA (IV)